Webinar: Lipid lowering landscape: New and emerging treatment approaches
Lipid disorders are the sixth most commonly managed condition in Australian general practice. However, the severity and optimal management of these disorders varies significantly.1Â Almost half of high-risk Australians prescribed lipid lowering therapy do not achieve their low-density lipoprotein (LDL) cholesterol targets for cardiovascular risk reduction.2Â
Streamed live during Heart Week 2022, this webinar explores the latest evidence on the management of high cholesterol in the context of cardiovascular risk reduction. Panellists discuss new and emerging pharmacological strategies for lipid lowering and translate the latest evidence to support preventative CVD risk assessment and management.
Duration:Â 1 hour
Date recorded:Â 4 May 2022
Topics covered:
Update on the mechanisms and role of new and emerging lipid lowering therapies
How to titrate and combine pharmacological lipid lowering therapies to optimise management
Strategies to identify and address non-adherence
Complimentary dietary and lifestyle counselling for people with hypercholesterolaemia
What general practices can do to champion CVD prevention and implement structured screening program
Kausik Ray
Professor of Public Heath, Department of Public Health and Primary Care & Honorary Consultant Cardiologist, Imperial College London & Imperial College NHS Trust
Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021-2022, Chair for Global Council for Heart Health. National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >100,000 citations and since 2018 has been recognised annually by Clarivate Analytics as among the top 0.1% of authors in global medicine. He led the international development program for Inclisiran, the first siRNA-based therapy for cholesterol-lowering approved globally, in addition to playing a key role in the development program of Bempedoic Acid and PCSK9 monoclonal antibodies. He initiated the Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry of FH, as well as multi-national European registries.
Karam Kostner
Professor of Medicine, University of Queensland & Director of Cardiology, Mater Public and Private Hospital Brisbane
Dr Kostner has been actively involved in cardiovascular research for 25 years, mainly in the area of lipoproteins, lipid lowering and atherosclerosis. Having published approximately 120 peer reviewed papers, book chapters, review articles and editorials, Dr Kostner has also given numerous invited lectures at cardiovascular meetings and is past president of the Cardiac Society of Australia and NZ, Queensland branch. Dr Kostner is an associate editor of Atherosclerosis and editorial board member and cardiovascular section editor of the European Journal Clinical Investigation and a regular reviewer for many journals, as well as being a NHMRC Grant Reviewer. Dr Kostner has also organised national and international conferences and has been the chair and organizer of three World Congresses of Clinical Lipidology.
Beata Bajorek
Academic Pharmacist, Royal North Shore Hospital & Professor, Graduate School of Health, University of Technology Sydney
Beata is a clinical pharmacist, having practiced in community & hospital settings, and is also a Research & Innovation Scholar for Hunter New England Local Health District and Research Affiliate of the Hunter Medical Research Institute’s Heart and Stroke Program. At the University of Technology Sydney, she is a member of the Stroke Research Group, UTS-Heart Foundation Strategic Partnership group, and SPHERE Cardiac and Vascular Health Clinical Academic Group. Her research focuses on collaborative, multidisciplinary interventions to optimise pharmacotherapy in cardiovascular and stroke care. She is involved in the development of practice-based tools and Australian guidelines for the National Stroke Foundation and Heart Foundation, is a co-author of the Heart Foundation’s ‘Improving Adherence in Cardiovascular Care: A Toolkit for Health Professionals’, and has been an expert speaker for the National Prescribing Service regarding evidence-based medicine in cardiovascular therapeutics.
Gary Deed
GP, Mediwell Medical Clinic & Adjunct Senior Research Fellow, Monash University (Melbourne)
Dr Gary Deed is a general practitioner with a passionate interest in promoting quality patient care of diabetes in general practice through education, development of resources including guidelines, policy development, research and strategic collaboration. He is the Chair of the Diabetes Specific interest network for the Royal Australian College of General Practitioners (RACGP), and a Ministerial appointment to the Commonwealth Diabetes Implementation Reference Group for Australia. He is the editor for the General Practice management of type 2 diabetes guideline for the RACGP. He is an Adjunct Senior Research Fellow of Monash University and helps co-ordinates the NHMRC funded ‘STAREE’ STAtins in Reducing Events in the Elderly trial. He has published peer reviewed journal articles in diabetes and is an editor for Diabetes Therapy and adviser/editor for Endocrinology Today.
This event was hosted in partnership with the World Heart Federation.
REFERENCES
- Cooke G, et al. Common general practice presentations and publication frequency. Aust Fam Physician 2013; 42(1–2):65–8.
- Carrington MJ, et al. CODE RED: Overturning Australia’s cholesterol complacency. May 2020, Baker Heart and Diabetes Institute, Melbourne, Australia.
Last updated21 February 2024